

## Datasheet: HCA213P

**BATCH NUMBER 154841**

<b>Description:</b>	HUMAN ANTI INFLIXIMAB:HRP
<b>Specificity:</b>	INFLIXIMAB
<b>Other names:</b>	REMICADE
<b>Format:</b>	HRP
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD17841_hIgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			1/100 - 1/1000

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.01% Thiomersal
<b>Approx. Protein Concentrations</b>	Total protein concentration 0.1 mg/ml
<b>Immunogen</b>	Infliximab
<b>Specificity</b>	<b>Human Anti-Infliximab, clone AbD17841_hIgG1</b> is an anti-idiotypic antibody that

specifically recognizes the infliximab monoclonal antibody and inhibits the binding of infliximab to its target. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD17841\_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD17841\_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays.

Infliximab (branded as Remicade) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

Infliximab is directed against Tumor Necrosis Factor Alpha (TNF $\alpha$ ) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNF $\alpha$  expressing T-lymphocytes.

[View a summary of all Anti-Infliximab Antibodies.](#)

<b>Affinity</b>	The monovalent intrinsic affinity of this antibody in an unconjugated format was measured as $K_D=1.8$ nM by real time, label-free molecular interaction analysis on immobilized infliximab.
<b>ELISA</b>	This product may be used in as a detection antibody in an Infliximab bridging ELISA together with <a href="#">HCA212</a> as the capture reagent. Protocol: <a href="#">PK bridging ELISA to measure free drug</a>
<b>References</b>	1. Hernández-Breijo, B. <i>et al.</i> (2016) Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <a href="#">Biochem Pharmacol. Sep 21. pii: S0006-2952(16)30302-1. [Epub ahead of print]</a>
<b>Storage</b>	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade® is a registered trademark of Janssen Biotech Inc. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: <a href="https://www.bio-rad-antibodies.com/SDS/HCA213P">https://www.bio-rad-antibodies.com/SDS/HCA213P</a>

---

<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only
<b>Technical Advice</b>	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <a href="#">HuCAL Antibodies Technical Manual</a>

---

## Related Products

### Recommended Useful Reagents

[HUMAN ANTI INFLIXIMAB \(HCA212\)](#)

[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA214\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA215\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA216\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M371636:200612'

Printed on 03 May 2024